Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Dec;9(3):191-9.
doi: 10.1007/BF02341149.

Selective cytoplasmic and membrane changes induced by cisplatinum

Affiliations

Selective cytoplasmic and membrane changes induced by cisplatinum

M A Oberc-Greenwood et al. J Neurooncol. 1990 Dec.

Abstract

Cisplatinum (cis-dichlorodiammineplatinum II (NSC-119875], proven to be of therapeutic value in a variety of solid tumors, is thought to have DNA as its major target. Prior in vitro studies have suggested that it also induced cell membrane and cytoplasmic changes. To better understand glial tumor cell sensitivity to cisplatinum and to design more effective adjuvant therapy, three cisplatinum sensitive human glioma-derived cell lines, SNB-1, SNB-3, SNB-4, were examined by transmission electron microscopy for cisplatinum induced changes. Tumor cells were exposed to 25, 50, and 100 micrograms/ml cisplatinum in medium for varying time periods (4-72 hours). Four changes were consistent: cell rounding and reduced nuclear-cytoplasmic ratio, nuclear chromatin clumping, vesiculation and swelling of the golgi apparatus, and dilatation of the smooth endoplasmic reticulum. These morphologic changes are distinct for cisplatinum and unlike those induced by BCNU (plasma membrane blebbing) and AZQ (mitochondrial swelling and destruction) previously seen in our laboratory. The cellular events described here suggest that cytoplasmic, as well as nuclear, changes (occurring within the same time intervals) may both be relevant to the antitumor effects of cisplatinum.

PubMed Disclaimer

Similar articles

Cited by

  • Drug resistance in brain tumors.
    Feun LG, Savaraj N, Landy HJ. Feun LG, et al. J Neurooncol. 1994;20(2):165-76. doi: 10.1007/BF01052726. J Neurooncol. 1994. PMID: 7807193 Review.

References

    1. J Histochem Cytochem. 1983 Feb;31(2):307-17 - PubMed
    1. Cancer Res. 1987 Aug 1;47(15):3988-94 - PubMed
    1. J Natl Cancer Inst. 1983 Oct;71(4):725-33 - PubMed
    1. J Neurooncol. 1986;3(4):387-96 - PubMed
    1. Acta Neuropathol. 1986;69(3-4):295-308 - PubMed

LinkOut - more resources